Experimental antibody ADG206 targets Hard-to-Treat cancers in first human trial

NCT ID NCT05614258

Ongoing Disease control Sponsor: Adagene Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check safety, find the right dose, and see how the body handles the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADG206 (a CD137 agonist antibody)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 14 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMORS

Contacts and locations

Locations

Ashford Cancer Centre Research

Kurralta Park, South Australia, 5037, Australia
Monash Health

Clayton, Victoria, 3168, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.